Can I read Anaplastic Lymphoma Kinase Inhibitors: Risk of Cardiovascular Toxicities on EtoBox?

Anaplastic Lymphoma Kinase Inhibitors: Risk of Cardiovascular Toxicities is a Medicine article available to read on EtoBox.

What is Anaplastic Lymphoma Kinase Inhibitors: Risk of Cardiovascular Toxicities about?

Anaplastic lymphoma kinase inhibitors: risk of cardiovascular toxicities The risk of some cardiovascular toxicities, in particular pericarditis, may be increased in patients receiving anaplastic lymphoma kinase (ALK) inhibitors, according to a study conducted by researchers from Japan.The researchers assessed the cardiovascular toxicity profiles of five ALK inhibitors (alectinib, brigatinib, ceritinib, crizotinib and lorlatinib) using data from VigiBase, the World Health Organization (WHO) pharmacovigilance database, for the time period from 1968 up to December 2021.The disproportionality analysis of adverse-event reports from 19 911 ALK inhibitors users showed that pericarditis signals were detected with all five ALK inhibitors, with reporting odds ratios (RORs) ranging from 3.5 (95% CI 1.33-9.46) for brigatinib to 12.9 (95% CI 9.37-17.79) for ceritinib. The time to onset for pericarditis ranged from 52.5 days for alectinib to 166.5 days for crizotinib. For other cardiovascular toxicities, the profiles differed among the five ALK inhbitors. For torsade de pointes/QT prolongation, signals were detected for crizotinib (ROR, 5.0; 95% CI 3.72-6.77) and ceritinib (ROR, 4.2; 95% CI 2.17

Who reads Anaplastic Lymphoma Kinase Inhibitors: Risk of Cardiovascular Toxicities?

Publisher

Springer Science and Business Media LLC

Published

2023

Language

EN

Field

Medicine (Health Sciences)